Huixiao Hong received his Ph.D. in computational chemistry at Nanjing University, China, in 1990. From 1990 to 1992, he completed his postdoctoral fellowship at the Maxwell Institute at Leeds University in the United Kingdom and worked on a computer-assisted organic synthesis system. He was an Associate Professor of Computational Chemistry at Nanjing University from 1992 to 1995, where he investigated computer-assisted molecular design and developed a suite of software for analytical instrumentation simulations. From 1995 to 1998, Dr. Hong worked in the Laboratory of Medicinal Chemistry at the National Cancer Institute at the National Institutes of Health as a Visiting Scientist. He discovered and designed more than 60 potent HIV integrase inhibitors and cyclooxygenase (COX) inhibitors through molecular modeling and pharmacophore searching. He also identified a mononucleotide-binding site in HIV integrase and elucidated the stereoselective binding mode of ibuprofen in COX1 using docking and molecular-dynamics simulation. From 1998 to 2000, he held a Research Scientist position in Sumitomo Chemical Company in Japan, where he developed a computer-assisted organic chemical structure elucidation system, Spec2D, based on 2-dimentional NMR spectra. Dr. Hong joined the information technology and scientific computing contract under Z-Tech at FDA’s NCTR in 2000, where he conducted diverse analyses and methods development for chemoinformatics and bioinformatics, and served as the computational science group manager from 2002. Dr. Hong became a senior scientist at the US FDA’s National Center for Toxicological Research in 2007. His current research interests focus on quality control and quality assessment of genotyping data for genome-wide association studies, developing methods for analyzing and interpreting genetic, genomic, transcriptomic, proteomic, and metabonomic data.
Biography Updated on 28 April 2009